CDA | Evidence Driven
CDA | Evidence Driven

ripretinib

Details

Files
Generic Name:
ripretinib
Project Status:
Complete
Therapeutic Area:
Gastrointestinal stromal tumours
Manufacturer:
Medison Pharma Canada Inc.
Brand Name:
Qinlock
Project Line:
Reimbursement Review
Project Number:
PC0265-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open16-Sep-21
Call for patient/clinician input closed05-Nov-21
Clarification:

- Patient input submission received from CanCertainty and GIST Sarcoma Life Raft Group Canada (LRGC)

Submission received15-Oct-21
Submission accepted29-Oct-21
Review initiated01-Nov-21
Draft CADTH review report(s) provided to sponsor for comment20-Jan-22
Deadline for sponsors comments31-Jan-22
CADTH review report(s) and responses to comments provided to sponsor25-Feb-22
Expert committee meeting (initial)09-Mar-22
Draft recommendation issued to sponsor22-Mar-22
Draft recommendation posted for stakeholder feedback31-Mar-22
End of feedback period14-Apr-22
Final recommendation issued to sponsor and drug plans28-Apr-22
Final recommendation posted16-May-22
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)12-May-22
CADTH review report(s) posted25-Aug-22

Files

Recommendation and Reasons View PDF
Clinical and Pharmacoeconomic combined Report View PDF
Stakeholder feedback on Draft Recommendation View PDF
Last Updated : August 25, 2022